Subcutaneous anakinra in the management of refractory MIS-C in FrancePediatrics Original Research Published on 2024-02-232024-09-05 Journal: Frontiers in Pediatrics [Category] update2024, [키워드] Anakinra COVID-19 Epidemiology interleukin-1 multisystem inflammatory syndrome in children myocarditis [DOI] 10.3389/fped.2024.1270878 PMC 바로가기 [Article Type] Pediatrics Original Research
NLRP3 inflammasome activation and symptom burden in KRAS -mutated CMML patients is reverted by IL-1 blocking therapyReport Published on 2023-12-192024-09-05 Journal: Cell Reports Medicine [Category] update2024, [키워드] Anakinra CMML IL-1 blockers Inflammation KRAS myelodysplastic syndromes myeloproliferative neoplasms NLRP3 blockers NLRP3 inflammasome RAS mutations [DOI] 10.1016/j.xcrm.2023.101329 PMC 바로가기 [Article Type] Report
Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trialsInfectious Diseases Published on 2023-05-182024-09-05 Journal: Annals of Medicine [Category] update2024, [키워드] Anakinra canakinumab COVID-19 interleukin-1 SARS-CoV-2 [DOI] 10.1080/07853890.2023.2208872 PMC 바로가기 [Article Type] Infectious Diseases
Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patientsLetter to the Editor Published on 2023-02-062024-09-05 Journal: European journal of internal medicine [Category] update2024, [키워드] acute respiratory distress syndrome Anakinra COVID-19 Mortality Tocilizumab [DOI] 10.1016/j.ejim.2023.01.024 PMC 바로가기 [Article Type] Letter to the Editor
Design of a multicenter randomized clinical trial for treatment of Alcohol-Associated Hepatitis ☆ ☆☆ ☆☆☆Article Published on 2023-01-182024-09-05 Journal: Contemporary Clinical Trials Communications [Category] update2024, [키워드] Alcohol-associated hepatitis Anakinra Model for end-stage liver disease (MELD) multicenter clinical trial Prednisone zinc sulfate [DOI] 10.1016/j.conctc.2023.101074 PMC 바로가기 [Article Type] Article
An EUA for anakinra (Kineret) for COVID-19Article Published on 2022-12-122023-07-11 Journal: The Medical letter on drugs and therapeutics [Category] COVID19(2023년), [키워드] actemra adverse effects Anakinra Baricitinib Corticosteroids COVID-19 Dexamethasone dosage Drug interactions Efficacy lactation Olumiant Pregnancy Remdesivir Safety Tocilizumab Veklury
High-dose corticosteroids in patients hospitalized for COVID-19 pneumonia: an observational study of comparative effectivenessObservational Study Published on 2022-12-012023-07-10 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), [키워드] Anakinra Corticosteroids COVID-19 infections Mortality [DOI] 10.1016/j.ijid.2022.10.023 PMC 바로가기 [Article Type] Observational Study
Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implicationsReview Published on 2022-11-012023-07-10 Journal: EBioMedicine [Category] COVID19(2023년), [키워드] Anakinra C-reactive protein canakinumab Colchicine COVID-19 IL-18 IL-1β NLRP3 inflammasome SARS-CoV-2 [DOI] 10.1016/j.ebiom.2022.104299 PMC 바로가기 [Article Type] Review
Challenges in diagnosing COVID-19 related disease in pediatric patients with rheumatic diseaseArticle Published on 2022-10-152022-11-15 Journal: Modern rheumatology [Category] 진단, [키워드] abdominal pain Administered Anakinra challenge chest pain children clinical Clinical characteristics coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 dermatomyositis diagnosing Diagnosis disease elevated evaluated Features Fever fraction function Immunoglobulin infiltration Inflammatory Inflammatory marker juvenile idiopathic arthritis Laboratory Mediterranean fever Methylprednisolone MIS-C multisystem inflammatory syndrome in children (MIS-C) myalgia outcome overlap Patient patients Pediatric patient Pneumonia raise Rash rheumatic disease Rheumatic diseases Symptom syndrome the patient [DOI] 10.1093/mr/roab112 PMC 바로가기
Current evidence on the use of anakinra in COVID-19Review article Published on 2022-10-012022-10-05 Journal: International immunopharmacology [Category] COVID19(2023년), SARS, 바이오마커, 임상, 진단, 치료제, [키워드] acute respiratory distress syndrome administration Anakinra approval clinical evidence clinical status COVID-19 COVID-19 patient COVID-19 patients current cytokine cytokine release Cytokine release syndrome Cytokine storm dose early stage effective Evidence IL-1 IL-1 receptor antagonist Immunomodulatory agent include inhibit interleukin-1 intravenous knowledge management mechanical ventilation multiple organ failure off-label Prevent progression Remdesivir required secondary hemophagocytic lymphohistiocytosis shown syndrome the disease the SARS-CoV-2 therapeutic effect therapeutic effects therapy Treatment treatment approach viral replication [DOI] 10.1016/j.intimp.2022.109075 [Article Type] Review article